/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

KEZAR LIFE SCIENCES INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$6.24 0.0146(1.46%) KZR at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 6.22
Highest Today 6.24
Today’s Open 6.22
Prev. Close 6.15
52 Week High 7.25
52 Week Low 3.53
Day’s Range: Low 6.22 High 6.24
52-Week Range: Low 3.53 High 7.25
1 day return -
1 Week return +0.81
1 month return +1.63
3 month return +61.24
6 month return +45.53
1 year return -12.05
3 year return -12.42
5 year return -3.12
10 year return -

Institutional Holdings

TANG CAPITAL MANAGEMENT LLC 9.83

Suvretta Capital Management, LLC 9.79

BML Capital Management LLC 8.67

Avidity Partners Management LP 6.86

Vanguard Group Inc 3.77

Biotech Growth Ord 2.63

Orbimed Advisors, LLC 2.63

Vanguard Total Stock Mkt Idx Inv 2.54

Stonepine Capital Management Llc 2.32

ADAR1 Capital Management LLC 2.01

Peapod Lane Capital LLC 1.57

Ikarian Capital, LLC 1.46

BlackRock Inc 1.33

Renaissance Technologies Corp 1.19

Qiming U.S. Ventures Management, LLC 1.13

Shay Capital LLC 0.92

Geode Capital Management, LLC 0.89

Sphera Funds Management Ltd. 0.80

Two Sigma Advisers, LLC 0.75

Vanguard Institutional Extnd Mkt Idx Tr 0.72

Bridgeway Capital Management, LLC 0.56

Bridgeway Ultra-Small Company 0.56

Fidelity Extended Market Index 0.46

Dimensional Fund Advisors, Inc. 0.41

RBF LLC 0.39

Fidelity Global Micro-Cap F 0.31

iShares Micro-Cap ETF 0.19

Fidelity Total Market Index 0.15

DFA US Targeted Value I 0.15

Extended Equity Market Fund K 0.14

Northern Trust Extended Eq Market Idx 0.13

NT Ext Equity Mkt Idx Fd - L 0.13

Dimensional US Targeted Value ETF 0.12

Fidelity Series Total Market Index 0.11

Spartan Extended Market Index Pool F 0.11

Dimensional US Small Cap ETF 0.07

Vanguard Instl Ttl Stck Mkt Idx Tr 0.06

NT Ext Equity Mkt Idx Fd - NL 0.06

DFA US Micro Cap I 0.05

Vanguard Balanced Index Inv 0.05

Market Status

Strong Buy: 3

Buy: 0

Hold: 3

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 45.04 M

PB Ratio 0.5472

PE Ratio 0.0

Enterprise Value -34.90 M

Total Assets 144.68 M

Volume 25814

Company Financials

Annual Revenue FY23:7000000 7.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-87791000 -87.8M, FY22:-65316000 -65.3M, FY21:-53279000 -53.3M, FY20:-38990000 -39.0M, FY19:-31531000 -31.5M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-227000 -0.2M, Q2/2025:null 0.0M, Q1/2025:-251000 -0.3M, Q3/2024:null 0.0M, Q2/2024:-261000 -0.3M

Quarterly Net worth Q3/2025:-11227000 -11.2M, Q2/2025:-13704000 -13.7M, Q1/2025:-16556000 -16.6M, Q3/2024:-20313000 -20.3M, Q2/2024:-21547000 -21.5M

Fund house & investment objective

Company Information Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 55

Industry Biotechnology

CEO Dr. Christopher J. Kirk Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow